Cancel
Locus Biosciences
See Linkedin
Locus Biosciences Employees
8 people indexed:
-
Ana Sanchez
Vice President of Research and Development
q1r.t1p746f@q66ykqwj7.6fv Sign up to see emailx2d.30tyrk4@8ryjxgfqk.94g Sign up to see email -
Jamie Kime
Vice President of Clinical Operations and CMC Operations
n4f62.7w8x@p54652qr6.v3w Sign up to see emailf34yx.83nn@w3wvz1n38.h2d Sign up to see email -
8y5.0z97h7@ff9958914.q2v Sign up to see email
-
7rzft6.wt122@9dg510rt7.5g5 Sign up to see email
-
jzj2.0f17dx@766txa5fw.waz Sign up to see email
-
Paul Garofolo
Co-founder and Chief Executive Officer
dtx4.edtz818h@1nq2nwt81.91e Sign up to see emailvhw3.8hhek1j8@yj4e2dq47.z65 Sign up to see email -
3tt6.33z@4rg283x0r.v02 Sign up to see email
-
Wendy Summers
Vice President of Pharmaceutical Operations and Technology
gj9tk.x08p0hf@52020fvvp.q2q Sign up to see email44f9t.hxp41g6@z2qjfjtf9.02v Sign up to see email
Locus Biosciences Company Information
Locus Biosciences is an innovative biotechnology company dedicated to tackling antimicrobial resistance and diseases associated with the microbiome. The company has developed the world’s most advanced platform for selectively eliminating pathogenic bacteria from the human body without harming beneficial bacteria. This capability is enhanced by their use of CRISPR technology to engineer bacteriophages specifically targeting harmful bacterial species such as E. coli, P. aeruginosa, S. aureus, and K. pneumoniae. Locus Biosciences has received significant support, including a $23.9 million funding from BARDA, to advance the first Phase 2 trial of their CRISPR-engineered bacteriophage therapy. Additionally, the company operates a state-of-the-art biologics manufacturing facility, spanning 10,000 sq ft, which was recognized as the ISPE 2021 ‘Facility of the Year’. This facility supports the transition from early development to early commercial production. Locus Biosciences also collaborates with notable partners like Janssen Pharmaceuticals and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to further their product development. Their approach integrates high-throughput robotics and next-generation DNA sequencing for efficient bacteriophage discovery, positioning them at the forefront of biotechnological innovation in the field of microbiome health.
Report inaccurate information
Report inaccurate information
